• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

18.45 -0.69 (-3.61%)
Streaming Delayed Price Updated: 2:09 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200,007
Open 19.14
Bid (Size) 18.41 (100)
Ask (Size) 18.49 (300)
Prev. Close 19.14
Today's Range 18.18 - 19.27
52wk Range 3.670 - 24.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗
May 08, 2026
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across... 
Via MarketBeat
News headline image
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
May 08, 2026
From BioAge Labs, Inc.
Via GlobeNewswire

Performance

YTD
+43.8%
+43.8%
1 Month
+14.0%
+14.0%
3 Month
-7.7%
-7.7%
6 Month
+130.3%
+130.3%
1 Year
+362.4%
+362.4%

More News

Read More
News headline image
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
May 04, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
April 21, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
April 13, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
March 24, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
January 21, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Proposed Public Offering
January 20, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
January 20, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 12, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
Tuesday's after hours session: top gainers and losers ↗
January 06, 2026
Via Chartmill
News headline image
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗
December 13, 2025
Via The Motley Fool
News headline image
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
December 04, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
November 07, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗
November 06, 2025
Via Chartmill
News headline image
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 06, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗
November 05, 2025
Via The Motley Fool
News headline image
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗
October 29, 2025
Via The Motley Fool
News headline image
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗
October 26, 2025
Via The Motley Fool
News headline image
Here are the top movers in Thursday's session. ↗
October 23, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
October 23, 2025
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
October 23, 2025
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
October 23, 2025
Via Chartmill

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?
Yes, BioAge Labs, Inc. - Common Stock is publicly traded.
What exchange does BioAge Labs, Inc. - Common Stock trade on?
BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioAge Labs, Inc. - Common Stock?
The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market
What is the current price of BioAge Labs, Inc. - Common Stock?
The current price of BioAge Labs, Inc. - Common Stock is 18.45
When was BioAge Labs, Inc. - Common Stock last traded?
The last trade of BioAge Labs, Inc. - Common Stock was at 05/14/26 02:09 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap